ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker

查看全文 作　　者：Yuning [1,2]Chen;Ya-Nan [2,3]Zhang;Renhong [4]Yan;Guifeng [1]Wang;Yuanyuan [4]Zhang;Zhe-Rui [2,3]Zhang;Yaning [5]Li;Jianxia [6]Ou;Wendi [1,2]Chu;Zhijuan [1,2]Liang;Yongmei [1,2]Wang;Yi-Li [7,9]Chen;Ganjun [7]Chen;Qi [1]Wang;Qiang [4]Zhou;Bo [3,8]Zhang;Chunhe [1,2,6,7,9]Wang

机构地区：[1]Biotherapeutics Discovery Research Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;[2]University of Chinese Academy of Sciences,Beijing,China;[3]Key Laboratory of Special Pathogens and Biosafety,Wuhan Institute of Virology,Center for Biosafety Mega-ScienceChinese Academy of Sciences,Wuhan,Hubei,China;[4]Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,and Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;[5]Beijing Advanced Innovation Center for Structural Biology,Tsinghua-Peking Joint Center for Life Sciences,School of Life Sciences,Tsinghua University,Beijing,China;[6]School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing,Jiangsu,China;[7]Dartsbio Pharmaceuticals,Zhongshan,Guangdong,China;[8]Drug Discovery Center for Infectious Disease,Nankai University,Tianjin,China;[9]Fudan University,School of Pharmacy,Shanghai,China

出　　处：《Signal Transduction and Targeted Therapy》索引2021年第6卷第9期,共9页

基　　金：This work was supported by the China National Major Scientific and Technological Special Project for'Significant New Drugs Innovation and Development'(2019ZX09732002-006);the Strategic Priority Research Program of the Chinese Academy of Sciences(CAS)(XDA12020223 and XDA12020330);the National Natural Science Foundation of China(81872785,81673347,31971123,32022037,81920108015,and 31930059);Shanghai Municipal Commission of Science and Technology of China(17431904400 and 19YF1457400);Institutes for Drug Discovery and Development,Chinese Academy of Sciences(CASIMM0120202008 and CASIMM0120202007);the National Key R&D Program(2020YFA0509303);Major Scientific and Technological Special Project of Zhongshan City(191022172638719 and 210205143867019);the Key R&D Program of Zhejiang Province(2020C04001);the SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province(2020C03129);the Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou,Westlake Education Foundation and Tencent Foundation. 摘　　要：The evolution of coronaviruses,such as SARS-CoV-2,makes broad-spectrum coronavirus preventional or therapeutical strategies highly sought after.Here we report a human angiotensin-converting enzyme 2(ACE2)-targeting monoclonal antibody,3E8,blocked the S1-subunits and pseudo-typed virus constructs from multiple coronaviruses including SARS-CoV-2,SARS-CoV-2 mutant variants(SARS-CoV-2-D614G,B.1.1.7,B.1.351,B.1.617.1,and P.1). 关键词：ACE2 MONOCLONAL prevention

相关文献

参考文献（45）
引证文献（3）
耦合文献（122）

参考文献(45)

引证文献(3)

耦合文献(122)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker

参考文献(45)

引证文献(3)

耦合文献(122)

用户提示